Insmed Inc (INSM)vsStoke Therapeutics Inc (STOK)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
STOK
Stoke Therapeutics Inc
$33.79
+5.00%
HEALTHCARE · Cap: $2.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 229% more annual revenue ($606.42M vs $184.42M). INSM leads profitability with a -2.1% profit margin vs -3.7%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
STOK
Avoid18
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.4% — below average capital efficiency
Revenue declined 93.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : STOK
STOK has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : STOK
The primary concerns for STOK are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
STOK carries more volatility with a beta of 1.19 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
STOK generates stronger free cash flow (-31M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Stoke Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?